IKI. N. Kozhanova

I. N. Kozhanova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


I. N. Kozhanova has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Drug resistance index calculation algorithm: methodology and practical application

    by T. Malinka, N. Kheifets, I. Kozhanova, Т. В. Малинка, Н. Е. Хейфец, И. Н. Кожанова

    Objective . To adapt the drug resistance index calculation methodology to electronic databases and drug consumption analysis tools available in the Republic of Belarus and to develop instructions detailing the sequence of steps required for the correct application of the methodology. Materials and methods . This study is methodological. It is based on a methodology for calculating the integrated drug resistance index. WHONET software, used to generate samples of microorganisms and their susceptibility to antimicrobials, is considered as the source of initial data. A demonstration example using simulated data is used to illustrate the method. Results . A step-by-step process for calculating the drug resistance index is presented, including formalization of all stages of data processing and indicator aggregation. The demonstration example illustrates the calculation sequence and the specifics of interpreting the final index value. Conclusion . Proposed approach ensures transparency and reproducibility in calculating the integrated drug resistance index and can be used to standardize data analysis. Detailed methodology facilitates its implementation in scientific and practical activities, objectifying it as a tool for making management decisions in the field of antibacterial therapy management.

  • Open Access

    Классификация AWaRe – готовый инструмент для работы или подспорье для разработки локальных актов

    by Т.в. Малинка, И.н. Кожанова, Н.е. Хейфец

    Improving the quality of management of antimicrobial therapy as a medical technology in healthcare settings is one of the main goals of the World Health Organization's global plan to combat antimicrobial resistance. As part of this activity, it is relevant to search for and implement into practice effective methods for analyzing the consumption of this group of drugs.The purpose of this study is to determine the place of the AWaRe classification in the development of local antimicrobial therapy management programs.Methods. ABC/VEN analysis and DDD (ATC/DDD methodology) were used to analyze the consumption of antimicrobial drugs. The consumption of antibacterial drugs was analyzed using the AWaRe method, 2023, based on the DDD and the WHO list of main antibiotics by groups: “Access” (A), “Watch” (W), “Reserve” (R), “Not recommended” (N). Statistical processing of the results was carried out using descriptive statistics methods using the MS Office EXCEL 2016 program.Results. An analysis of antibiotic consumption in four multidisciplinary hospitals in Minsk for 2022 and 2023 was carried out using pharmacoepidemiological DDD methodology and AWaRe classification. The study determined the place of this tool in the development ofantibacterial therapy management programs.Conclusions. The study noted that the use of the AWaRe classification as part of the development of an antibacterial therapy management program can complement the niche of descriptive data analytics, that is, it will make it possible to describe the structure of consumption of antibacterial drugs using a formalized, stereotypical international tool. This tool further provides an opportunity to implement diagnostic tasksto develop measures to influence the policy and practice of using antibacterial drugs.

  • Open Access

    THE ECONOMIC BURDEN OF INVASIVE FORMS OF MENINGOCOCCAL INFECTION

    by E.N. Sergienko, I.N. Kozhanova, O.N. Romanova, A.D. Solodov, P.A. Scutova

    Relevance Invasive meningococcal infection (IMI) is a significant clinical problem and is associated with a high probability of severe complications and death. Vaccination programs against meningococcus can achieve significant clinical effectiveness and require significant financial costs. This makes it relevant to study the economic burden of meningococcal infection in the conditions of modern healthcare in order to obtain basic data for subsequent research in the field of evaluation of medical technologies. Aims To assess the economic burden of IMI in children in the conditions of healthcare in the Republic of Belarus. Material and methods a retrospective study using the “cost of illness” method was conducted for 22 children hospitalized in the city children’s infectious clinical diseases hospital in 2018-2019. All values are presented in belarusian rubles. The average ± standard deviation, minimum – maximum values, median [Q1, Q3], cost shares (%) are calculated for the cost values. The minimum– maximum values and median [Q1, Q3] were calculated for the age of the patients. Results taking into account the costs of treatment in healthcare organizations of all patients studied, the share of direct costs of hospitalization was 29.0%, the share of direct costs of diagnosis - 7.2%, the share of direct costs of pharmacotherapy - 8.3%. A significant part of the costs accounted for observations after discharge and amounted to 55.4%. Conclusion a retrospective study of the economic burden of MI in the Republic of Belarus using the “cost of illness” method in patients hospitalized in a public health organization demonstrates a significant economic burden of this disease, which in the long term is primarily due to the presence of complications in the patient, as well as the impact of the patient’s death on the value of total costs.

  • Open Access

    Topical Issues of Specific Therapy of Chronic Thromboembolic Pulmonary Hypertension. Pharmacoeconomical Analysis of the Use of the Drug Riociguat

    by И.с. Романова, Д.ю. Рузанов, И.н. Кожанова, Т.а. Чак, А.в. Семёнов

  • Open Access

    Health technology assessment: factors affecting the results

    by I. N. Kozhanova

    Purpose:to identify factors influencing the results of health technology assessment (HTA).Methods.This analysis is based on previously performed clinical (pharmaco-) economic studies in the Republic of Belarus. The primary data analysis methods for inclusion in this publication have been cost-of-illness analysis (COI). The studies were carried out from 2010 to 2021. All costs are presented in US dollars based on exchange rates at the time of execution. Ranges are presented as maximum and minimum values.Results.The analysis of the influence of the stage of the disease, the stage of medical care, the form of release for drugs, the age of the target population for the use of health technology, the source of information on the price of technology on the results of the procedure for assessing medical technology has been performed. Evaluation of the ratio of the results of COI for implementation the clinical protocol and capabilities of the healthcare system (stable angina pectoris, type 2 diabetes mellitus), as well as for a number of special health technologies (hemophilia A; post-stroke spasticity; mantle cell lymphoma; chronic lymphocytic leukemia; chronic myeloid leukemia; lung cancer).Conclusions.It can be concluded that there is a need for clear formulations of goals and objectives at the stage of formation of the study design, considering the influence of the position of the researcher, the source of costs, the selected population, form of release (for drugs) on the main clinical and economic indicators and on the subsequent interpretation of the results of HTA.